CN Patent

CN119968202A — 用于预防或治疗心血管衰老疾病的包含依那格列净的药物组合物

Assigned to Daewoong Pharmaceutical Co Ltd · Expires 2025-05-09 · 1y expired

What this patent protects

本发明涉及用于预防或治疗心血管衰老疾病的药物组合物，其包含作为活性成分的依那格列净。本发明的依那格列净在预防和治疗由血管内皮衰老引起的内皮功能障碍以及与之相关的心血管衰老疾病中表现出优异的效果。

USPTO Abstract

本发明涉及用于预防或治疗心血管衰老疾病的药物组合物，其包含作为活性成分的依那格列净。本发明的依那格列净在预防和治疗由血管内皮衰老引起的内皮功能障碍以及与之相关的心血管衰老疾病中表现出优异的效果。

Drugs covered by this patent

Jardiance (empagliflozin) · Boehringer Ingelheim

Patent Metadata

Patent number: CN119968202A
Jurisdiction: CN
Classification: —
Expires: 2025-05-09
Drug substance claim: No
Drug product claim: No
Assignee: Daewoong Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.